Athersys, Inc. (ATHX): history, ownership, mission, how it works & makes money

A Brief History of Athersys, Inc. (ATHX)

Foundation and Early Development

Athersys, Inc. was founded in 1995 in Cleveland, Ohio. The company originally focused on therapeutic applications in regenerative medicine. By 2008, Athersys had developed MultiStem®, a proprietary stem cell product designed for various therapeutic applications.

Key Product Developments

MultiStem is being evaluated for multiple conditions, including acute ischemic stroke, cardiovascular disease, and inflammatory bowel disease. A significant landmark for Athersys occurred in 2019 when the company announced positive results from a Phase 2 clinical trial for stroke.

Public Offering and Financial Growth

In June 2014, Athersys went public on the NASDAQ under the ticker symbol ATHX. As of 2023, Athersys has raised approximately $100 million through various public offerings.

Partnerships and Collaborations

Athersys has formed strategic partnerships to enhance its product development. In 2018, the company entered into a collaboration with Healios K.K., a Japanese regenerative medicine company, focusing on the development and commercialization of MultiStem for ischemic stroke.

Recent Performance and Market Data

As of October 2023, Athersys' market capitalization stands at approximately $250 million. The company reported revenue of $2 million for the second quarter of 2023, primarily from grant funding and collaborations.

Challenges and Future Directions

Despite advancements, Athersys faces challenges including clinical trial delays and market competition. The company's focus remains on advancing MultiStem through clinical trials to fulfill unmet medical needs.

A Who Owns Athersys, Inc. (ATHX)

Shareholder Composition

Athersys, Inc. (ATHX) has a diverse shareholder base comprising institutional investors, mutual funds, and retail investors. As of the latest filings, the following table outlines the key shareholders and their respective ownership stakes.

Recent Financial Data

As of the most recent quarter, Athersys reported the following financial metrics:

Insider Ownership

Insider ownership plays a critical role in understanding the governance of Athersys. The following table includes notable insiders and their ownership stakes.

Recent Developments

Recent announcements in the context of ownership and capital structure include:

• Equity financing raised $20 million in Q3 2023.
• Athersys entered a strategic partnership with a leading pharmaceutical company in July 2023.
• Institutional holdings increased by 15% from Q1 2023 to Q3 2023.

Conclusion

The ownership structure of Athersys, Inc. reflects a balanced mix of institutional shareholders alongside significant retail investment. The financial metrics indicate ongoing efforts for growth and exploration of strategic partnerships to enhance shareholder value.

Athersys, Inc. (ATHX) Mission Statement

Overview of the Mission Statement

Athersys, Inc. is committed to advancing regenerative medicine through the development of innovative therapies. The company’s mission emphasizes the aim of improving patient outcomes and addressing significant unmet medical needs using its proprietary MultiStem technology platform.

Strategic Focus Areas

• Regenerative Medicine: Focused on creating therapies that regenerate damaged tissues and organs.
• Clinical Development: Actively engaged in various clinical trials to validate its therapies for multiple conditions.
• Global Partnerships: Seeking collaborations to enhance research capabilities and market penetration.
• Patient-Centric Approach: Prioritizing patient needs in the development of treatment solutions.

Financial Data

As of Q3 2023, Athersys reported total revenues of $3.8 million. The company has incurred a net loss of $5.2 million during the same period.

Stock Performance

The stock price of Athersys, Inc. (ATHX) has shown significant volatility. As of October 2023, the share price is approximately $0.23, reflecting a year-to-date change of approximately -40%.

Recent Developments

The company recently announced a partnership with Rallybio Corporation to advance the development of its programs, expected to lead to enhanced funding and research opportunities.

Clinical Trials Overview

Athersys is conducting several clinical trials, focusing on conditions such as ischemic stroke, acute respiratory distress syndrome (ARDS), and traumatic brain injury. The current pipeline includes:

Funding and Investment Activities

Athersys has raised approximately $20 million through various funding rounds in 2023, aimed at supporting its clinical development and operational activities.

Market Opportunity

The global market for regenerative medicine is projected to reach $78 billion by 2027, with a CAGR of approximately 23%. Athersys aims to capture a substantial share of this market through its innovative product offerings.

Collaborative Efforts

• Partnership with Rallybio Corporation
• Collaboration with various academic institutions
• Joint ventures with biotechnology firms

How Athersys, Inc. (ATHX) Works

Company Overview

Athersys, Inc. is a biotechnology company that focuses on regenerative medicine and cell therapy. Its primary goal is to develop innovative therapeutic solutions for various diseases, including neurological, cardiovascular, and inflammatory conditions.

Business Model

The business model of Athersys is centered on the development and commercialization of its proprietary MultiStem® cell therapy. MultiStem® is an allogeneic stem cell-based therapy designed to treat a variety of conditions, leveraging a unique mechanism of action.

Key Therapeutic Areas

• Neurological Disorders
• Cardiovascular Diseases
• Inflammatory Diseases

Pipeline Products

Athersys has a diverse pipeline with several product candidates in various stages of development. The key products include:

Financial Performance

As of October 2023, Athersys reported the following financial figures:

Collaborations and Partnerships

Athersys actively engages in collaborations to enhance its research and development efforts. Notable partnerships include:

• Collaboration with HEALIOS K.K. for the development of MultiStem® in Japan.
• Partnership with Fujifilm for commercial manufacturing capabilities.

Regulatory Status

Athersys is actively pursuing regulatory approvals for its therapies. The company has filed for fast track designation and orphan drug status from the FDA for its MultiStem® therapy.

Shareholder Information

As of the latest reports, Athersys has the following key shareholder statistics:

Recent Developments

In October 2023, Athersys announced significant progress in its Phase 3 trial for ischemic stroke, highlighting the potential for a positive outcome that could lead to market approval.

How Athersys, Inc. (ATHX) Makes Money

Revenue Streams

Athersys, Inc. generates revenue primarily through several key avenues:

• Licensing Agreements
• Collaborative Research and Development
• Grants and Funding
• Clinical Trials

Licensing Agreements

Athersys has entered into licensing agreements with various pharmaceutical and biotechnology companies to develop and commercialize its stem cell therapy products. For instance, in 2015, the company entered into a licensing agreement with Angiotech Pharmaceuticals with a potential value exceeding $200 million.

Collaborative Research and Development

The company collaborates with organizations such as Otsuka Pharmaceutical Co., Ltd. and has received funding for various clinical projects. In 2021, Athersys reported a partnership with Otsuka that could provide up to $160 million in total funding.

Grants and Funding

Athersys also secures government and private grants to support its research initiatives. In 2020, the National Institutes of Health (NIH) awarded Athersys a grant of $1.3 million to support its studies on the use of MultiStem® for treating traumatic brain injury.

Clinical Trials

The company conducts clinical trials to evaluate the safety and efficacy of its products and receives funding from partners for these activities. Athersys reported spending approximately $7.1 million on research and development in the first quarter of 2023 alone.

Financial Overview

Below is a summary of Athersys, Inc.'s financial performance based on their latest reported figures:

Market Potential

Athersys targets significant market opportunities in areas such as neurological disorders and immunological therapies. The global stem cell market was valued at approximately $9.8 billion in 2021 and is expected to expand at a compound annual growth rate (CAGR) of around 10% through 2028.

Stock Performance

As of October 2023, Athersys, Inc. (ATHX) shares are trading at approximately $0.36, reflecting a market capitalization of around $100 million.

Conclusion

Athersys, Inc. relies on diverse revenue streams including licensing, partnerships, and grant funding, which are crucial for sustaining its operations and advancing its innovative therapies.